Circulation Reports
Online ISSN : 2434-0790
Heart Failure
Importance of Optimized Guideline-Based Therapy for Preventing Rehospitalization of Chronic Heart Failure Patients ― From the KUNIUMI Acute Cohort ―
Susumu OdajimaHidekazu TanakaWataru FujimotoKoji KurodaSoichiro YamashitaJunichi ImanishiMasamichi IwasakiTakashi TodorokiMasanori OkudaTakatoshi HayashiAkihide KonishiMasakazu ShinoharaRyuji TohKen-ichi Hirata
著者情報
ジャーナル オープンアクセス HTML

2021 年 3 巻 9 号 p. 511-519

詳細
抄録

Background:Because the effectiveness of strengthening guideline-based therapy (GBT) to prevent heart failure (HF) rehospitalization of chronic HF patients remains unclear, this study investigated the characteristics of HF patients in the Kobe University Heart Failure Registry in Awaji Medical Center (KUNIUMI) acute cohort.

Methods and Results:We studied 254 rehospitalized HF patients from the KUNIUMI Registry. Optimized GBT was defined as a Class I or IIa recommendation for chronic HF based on the guidelines of the Japanese Circulation Society. The primary endpoint was all-cause death or first HF rehospitalization after discharge. Outcomes tended to be more favorable for patients who had rather than had not received optimized GBT (hazard ratio [HR] 0.82; 95% confidence interval [CI] 0.57–1.19; P=0.27). Similarly, among New York Heart Association (NYHA) Class IV patients, outcomes tended to be more favorable for those who had rather than had not undergone optimized GBT (HR 0.73; 95% CI 0.47–1.12; P=0.15). Importantly, outcomes were significantly more favorable among NYHA Class IV patients aged <79 years who had rather than had not undergone optimized GBT (HR 0.33; 95% CI 0.14–0.82; P=0.02). Multivariate Cox regression analysis showed that optimized GBT was the only independent factor for the prediction of the primary endpoint.

Conclusions:Optimized GBT can be expected to play an important role as the next move for chronic HF patients.

著者関連情報
© 2021, THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
前の記事 次の記事
feedback
Top